Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...